Matthew Gantz

Biography

CEO of OxThera AB. Former PathoGenesis, Chiron and BTG executive, who has built and led several successful high growth businesses in the US and Europe across the specialty pharma and medical device space in multiple therapeutic areas. Gained approval and successfully launched two rare disease drugs, TOBI and Voraxaze, in Europe and US respectively. Board member of SOBI, a publically listed Swedish Rare Disease Company and Life Sciences PA, the Pennsylvania Life Science industry association. Mr Gantz is a graduate of Princeton University and received his MBA from Harvard Business School. He also served as an infantry officer in the US Marine Corps.

Research Interest

Pharmaceutical Sciences, Lipid Technologies, Pharmaceutical formulations etc.